Kymera Therapeutics KYMR

HealthcareMarket cap $3B1 connection

Kymera develops targeted protein degraders - drugs that harness the cell's own protein recycling machinery (ubiquitin-proteasome system) to eliminate disease-causing proteins rather than just blocking them. Protein degradation can hit targets that traditional drugs cannot. Pipeline covers immunology and oncology.

Explore Kymera Therapeutics on the interactive map Relationship timeline Find a path to another company

Partners 1

Strategic partnerships, joint products and alliances

PfizerHealthcare · $160BSanofi $1.35B deal for Kymera IRAK4 degrader program

Other Healthcare companies

Eli Lilly UnitedHealth Novo Nordisk Johnson & Johnson AbbVie Merck AstraZeneca Thermo Fisher Novartis Abbott Labs

Embed this on your site

Show Kymera Therapeutics's network in an article or report - it updates as our data does.

<iframe src="https://vexmap.com/embed.html?co=KYMR" width="600" height="420" style="border:0;border-radius:12px;max-width:100%" title="Kymera Therapeutics on VexMap" loading="lazy"></iframe>

Preview

Relationships are compiled by VexMap from company filings, announcements and reporting, and last reviewed September 2026. Spotted something wrong? Tell us. Not investment advice.